icon-    folder.gif   Conference Reports for NATAP  
 
  Back grey_arrow_rt.gif
 
 
 
Resistance Through Week 48 in the DAWNING Study Comparing Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/r) Plus 2 NRTIs in Second-line Treatment
 
 
  Reported by Jules Levin
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018
 
Ruolan Wang,1Joe Horton,2Judy Hopking,3Karen King,2Kimberly Smith,1Michael Aboud,4Brian Wynne,5Jorg Sievers,4Mark Underwood1 1ViiV Healthcare, Research Triangle Park, NC, USA; 2Parexel International, Durham, NC, USA; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Brentford, UK; 5ViiV Healthcare, Philadelphia, PA, USA

0731181

0731182

0731183

0731184

0731185